Abstract: Alzheimer's Disease (AD) is caused by the deposition of insoluble and toxic amyloid peptides (A ) in the brain leading to memory loss and other associated neurodegenerative symptoms. To date there is limited treatment options and strategies for treating AD. Studies have shown that clearance of the amyloid plaques from the brain and thus from the blood could be effective in stopping and or delaying the progression of the disease. Small peptides derived from the A -42 sequence, in particular KLVFF, have shown to be effective binders of A peptides and thus could be useful in delaying progression of the disease. We have taken advantage of this property by generating the retro-inverso (RI) version of this peptide, ffvlk, in different formats. We are presenting a new detox gel system using poly ethylene glycol (PEG), polymerized and cross linked with the RI peptides. We hypothesize that detox gel incorporating RI peptides will act like a 'sink' to capture the A peptides from the surrounding environment. We tested these detox gels for their ability to capture biotinylated A -42 peptides in vitro. The results showed that the detox gels bound A -42 peptides effectively and irreversibly. Gels incorporating the tetramer RI peptide exhibited maximum binding capacity. The detox gel could be a potential candidate for treatment strategies to deplete the brain of toxic amyloid peptides.
INTRODUCTION
Alzheimer's disease (AD) is characterized by diffuse brain atrophy and the presence of senile plaques especially in the cortex and hippocampus. Plaques are composed mainly of small peptides (A ) generated by cleavage of the transmembrane protein, amyloid precursor protein (APP). To date, no physiological function has been ascribed to APP nor to A peptides. Secreted A is readily detected in CSF, plasma, and in medium conditioned by a wide variety of cultured cells [1] and can cross the blood brain barrier (BBB). Two peptides A -40 and A -42 are the main contributors to AD pathogenesis and play an important role in fibril and eventually plaque formation. A -40 is the major component of the secreted A , but a small percentage of A -42 is more important in the pathophysiology of AD. A -42 is believed to play a crucial role in the early stage of fibril formation because of its seeding effect and thus more "amyloidogenic". Synthetic A -42 forms amyloid fibrils in vitro much more readily than A -40 [2] , and there is substantiation that A -42 is deposited early and selectively in senile plaques [3] .
Studies have shown that hydrophobic core residues at 17-20 of A are crucial for the formation of beta sheets and for the amyloidogenic properties of the peptide. Substitution of these amino acids with hydrophilic amino acids reduces the capacity to form fibrils [4] . Structurally different D amino acids of A -42 namely klvff have the capability of binding A and preventing its assembly into amyloid fibrils [5, 6] . Molecular modeling suggested that association of the two homologous sequences leads to the formation of an atypical anti-parallel beta sheet structure stabilized primarily by interaction between the Lysine, Leucine and Phenylalanine residues. The self-recognition property of the peptide, KLVFF, without any additional amino acids has recently been confirmed [7] . Related studies focused on developing small peptide-like compounds that could recognize and bind A peptides avidly and specifically, while also being able to disrupt beta sheet structure [8] . Peptides that bind A -42 would promote clearance of A -42 peptides from brain or inhibit their aggregation into insoluble deposits. The use of retro-inverso (RI) peptides (composed of D-amino acids in the reverse sequence, ffvlk) has been tested [8] . Specificity is based on 5 amino acids. Avidity is based on using multiple copies of the binding peptide to capture target A peptide. The use of D-amino acids can provide resistance to peptidase digestion while preserving the natural KLVFF binding properties and multiple copies of the binding element can increase the avidity of interaction with fibrils prepared from A peptides.
We will now demonstrate that PEG carriers can be used to form hydrogels (defined as >90% water) that can be used as scaffolds for attaching multiple copies of RI peptides. Groups of these RI peptides will thereby be able to achieve stronger binding avidity to A peptides [8] and, consequently sequester these toxic A peptides. Essentially, these detox gels are made by covalently linking a particular RI peptide to poly(ethylene glycol) polymer chains. PEG was chosen as the building block of the new hydrogel-forming polymers based on its history of safety and non-toxicity [9] . In the present study, we have combined the features of the A binding agents with the properties of the subcutaneous hydrogel drug delivery system into a novel therapeutic system, namely, "detox depot". We hypothesize that a detox gel incorporating an RI peptide will act like a 'sink' to capture the A peptides from the surrounding environment. We tested several detox gels for their ability to capture biotinylated A -42 peptides in vitro. We have designed, synthesized and tested the dimeric (two copies of the monomer RI peptide) and tetrameric (four copies of the monomer RI peptide) peptides and prepared detox gels incorporating these peptides. The ability of detox gels with monomer, dimer or tetramer peptides to bind A -42 was examined and compared by an in vitro binding assay. The results showed that the detox gels bound A -42 peptides effectively and irreversibly and that gels incorporating the tetramer RI peptide exhibited maximum binding capacity. The detox gel could be a potential candidate for treatment strategies to deplete the brain and circulating amyloid peptides.
MATERIALS AND METHODS a) Preparation of Gels
Placebo gels were made by using, 8-arm PEG-NH2, (MW-10, 000) and VS-PEG-NHS (MW-3, -400, and SH-PEG-SH from Nektar Therapeutics Inc, AL). For 2% gels, approximately 1.5 x 10 -6 moles of PEG was used. VS-PEG-NHS at 1.2-fold molar ratio was added to PEG 8-arm solution very slowly (drop-wise) and mixed by light shaking and left at room temperature for 2 hours for reaction to be complete. This reaction produced PEG-VS 8 , which was distributed into 1.5 mL polypropylene tubes. For detox gels, 4 x10 -7 moles of peptide per gel was added to appropriate tubes and the reaction allowed to go for 6 hours. This way, the peptides were attached to 2-3 arms of the 8-arm PEG. At this point we had PEG-Peptide 3 -VS 5. For placebo (control) gel, PB (20 mM, pH=8.0) was used. Reaction was allowed to proceed for 2 -12 hours. For the last step, 3.25 x 10 -7 moles of "disulfide-linker" (HS-PEG 3,-400 -SH) was added to each tube and mixed to form the gels. Gels were stored at -4 o C, soaked in PB containing 0.005% sodium azide. Each gel was 100 l in volume and was made in 1.5 mL polypropylene tube. 2% (PEG) gels were used in all experiments.
b) Testing the Binding and Stability of Biotinylated A Peptides
Ability of biotinylated A peptides (1-42 and 1-40) to bind the retro inverso peptides (RI) were investigated by ELISA. RI monomer, dimer, tetramer, scrambled or an irrelevant peptide was immobilized on an NUNC immunosorbant plate (1 g/well). The samples were sonicated for 10 min. prior to plating. ELISA binding buffer (carbonate buffer pH 9.6) was used to ensure efficient binding of the peptide to the ELISA plate. After overnight incubation, the wells were blocked with 3% gelatin solution for 1 hour at 37 0 C. At the end of the incubation period, gelatin was discarded and wells probed with biotinylated A peptides, 1-42or 1-40 (1.5 g/ mL). The plates were incubated for one hour with the probe at 37 0 C followed by four washes with TBST (Tris buffered saline with Tween-20, 50 mM Tris, 150 mM NaCl and 0.5% Tween 20). To each well, 100 l of streptavidin conjugated with horseradish peroxidase at a dilution of 1: 10,000 was added and the plate incubated at 37 0 C for 1 hour. The plate was then washed again with TBST (for five times). Color was developed at room temperature using the color reagent mixture containing equal volumes of peroxidase substrate solutions A and B (as prescribed by KPL, MD, the manufacturer) and intensity was read in a plate reader at 595nm. Every plate contained triplicates of graded standards. Standard solutions were also sonicated for 10 min. prior to plating. OD results were calibrated against the standards and expressed as pmols A /mL binding solution.
c) Synthesis of Peptides
Peptide synthesis and characterization were performed at the William Keck Foundation Biotechnology Research Laboratory at Yale University. The peptides were purified by reverse-phase HPLC and analyzed by MALDI-TOF to confirm structure. an amidated C-terminus for peptidase resistance c) lysine residues for branching into parallel peptide chains d) 2 or 4 copies of the binding peptide sequence for avid binding, e) an extra lysine at the N-terminus of each sequence for solubility and binding, f) a cysteine residue for conjugating to a PEG carrier and g) a residue of -alanine at every branch point for flexibility of the structure.
d) Binding Assay
48 well culture plates were coated with 6 l of a protein mixture containing equal quantity of cottontail rabbit papilloma virus E-6 and E-7, glutathione S-transferase and BSA (3.5mg/mL final protein concentration) was added to each well containing 100 l ELISA binding buffer (Carbonate buffer, pH=9.6) and incubated o/n at 37 0 C. The coated wells were washed twice with 1 mL PB (10 mM, pH=7.0) and swelled gels were placed in the 48-well plate. Triplicate gels for each category were taken. A binding solution in PB was prepared containing 1.5 g biotinylated A -42 peptide (or 1.5 g biotinylated A -40 peptide/mL). The chosen volume was 1.0 mL since it was sufficient to submerge the gel throughout the experiment. This buffer was sonicated for 10 min and added to the well for incubation with the gels. At each timepoint, 10 l of binding solution was harvested from which 3 x 3 l was used for ELISA. Before taking the time-point aliquot, the binding solution was placed in a polypropylene tube and sonicated for 10 minutes. Sonication was found to be critical to prevent aggregation of A peptide. At the end of the experiment, gels were washed, transferred to PB containing no A peptide and incubated at 37 0 C for several days to assess the release, if any, of A peptide back into the medium. To account for possible dilution of A in this medium, the entire sample of 1 mL was lyophilized down to 15 l and triplicates of 5 l were plated on ELISA plates to measure A -42.
e) ELISA
Elisa was performed as described [10] . Briefly, harvested samples, in triplicates, were coated on 96 well plates (NUNC plates from Pierce, IL, 3 l/well, suspended in 100 l carbonate buffer, pH 9.6) and let stand overnight at 37 0 C. Samples were sonicated for 10 min. prior to coating. ELISA binding buffer (carbonate buffer pH 9.6) was used to ensure efficient binding of the peptide to the ELISA plate. After overnight incubation, wells were blocked with 3% gelatin solution for 1 hour at 37 0 C. At the end of the incubation period, gelatin was discarded and replaced with 100 l/well of streptavidin conjugated with horseradish peroxidase (Initial experiments to find out the linear response range derived a dilution of 1: 10,000) and the plate incubated at 37 0 C for 1 hour. Plates were then washed with TBST wash buffer (tris buffered saline with Tween-20, 50 mM Tris, 150 mM NaCl and 0.5% Tween 20) for 5 times. Color was developed at room temperature using the color reagent mixture containing equal volumes of peroxidase substrate solutions A and B (as prescribed by KPL, MD, the manufacturer) and color intensity was read in a plate reader. Every plate contained triplicates of graded standards. Standard for A -42biotin was determined in preliminary experiments to be linear in the range of 1 to 20 ng. Volume in each well was made up to 100 l with ELISA binding buffer. Standard solutions were also sonicated for 10 min. prior to plating. OD results were calibrated against the standards and expressed as pmols A /mL binding solution.
f) Amino Acid Analysis
Amino acid analysis is carried out on a Beckman Model 7300 ion-exchange instrument following a 16 hr hydrolysis at 115 degrees C in 100 l of 6 N HCl, 0.2% phenol that also contains 2 nmol norleucine. The latter serves as an internal standard to correct for losses that may occur during sample transfers, drying etc. After hydrolysis, the HCl is dried in a Speed Vac and the resulting amino acids dissolved in 100 l Beckman sample buffer that contains 2 nmol homoserine with the latter acting as a second internal standard to independently monitor transfer of the sample onto the analyzer. The instrument is calibrated with a 2 nmol mixture of amino acids and it is operated via the manufacturer's programs and with the use of their buffers. Data analysis is carried out on external computer using Perkin Elmer/Nelson data acquisition software.
RESULTS

Determination of binding of A -42 or A -40 Peptide to Immobilized RI Peptides
In order to validate the assay design and reagents that we generated, we first investigated the ability of biotinylated A peptides (1-42 and 1-40) to bind the binding element, the RI monomer, dimer and tetramer version on a direct ELISA. Monomer, dimer and tetramer peptides were immobilized on an ELISA plate (1ug /well) in triplicates. Every plate contained triplicates of graded standards. The wells were blocked and probed with biotinylated A -42 or A -40 peptides. Level of binding was measured quantitatively and results are presented in Fig. (1) . Results showed that there was significant and specific binding of biotinylated A peptides to all three RI peptides. Negligible binding was observed for scrambled or an irrelevant control peptide. These results validated the assay that we designed to quantitate the level of binding. In addition, the successful measurement showed that the peptides we synthesized were authentic. 
Binding of Biotinylated A -42 Peptides to Detox Gels
Next, we investigated the binding of biotinylated A -42 peptide to detox gels in a binding solution. Detox gels were prepared incorporating one of the RI peptide [monomer, dimer or tetramer version]. Negative control gels incorporated no peptide or peptide with same amino acid composition but with a scrambled sequence. Gels were incubated in a solution-containing target A -42. Binding was allowed to continue for 2 hours and samples were harvested at designated time points. A -42 remaining in the harvested binding solution was measured by ELISA. Results showed that gels containing RI peptide bound A -42 specifically and irreversibly (Fig. 2) . Such binding was not observed in the negative control gels and gels that incorporated the scrambled peptide. Gels incorporating the native peptide bound the A -42, but to a lesser extent than the RI peptide (data not show). There was a gradual reduction of the A -42 over time in the RI containing detox gels versus the control gels. We find that the binding is in the following order: placebo gel < monomer RI gel < dimer RI gel < tetramer RI gel. From a quantitative perspective, the weight of monomer, dimer or tetramer RI peptide in each gel was about 1 g. This corresponds about 1000 Da (molecular weight of the monomer RI peptide is about 700 Da ) for each repeating RI sequence in the dimer and tetramer peptides. Accordingly, the gel was linked to 1.0 nmol of RI peptide sequences (i.e. 1,000 ng x 1 nmol/1000 ng = 1.0 nmol). However, the RI peptide incorporated gel consistently bound only about 250 pmols of A peptide and was then saturated. Fig. (2) . Binding of biotinylated A -42 peptide to detox gel. Binding experiment performed with the detox gel (RI gel) and control gels as denoted. Binding assay was performed as described in the methods section. Pre-swelled individual gels were incubated in the binding solution containing phosphate buffer (10 mM, pH 7), biotinylated A -42 peptide (1.5 g/mL) at 37 0 C. Samples were harvested at 0, 30, 60, 90 and 120 minutes. Then the gels were washed and incubated in buffer containing no biotinylated A -42 peptide for up to 4 days at 37 0 C. Samples were collected at the end of 1 and 4 days to assess the release of the biotinylated A -42 peptide back into the medium as described in Materials and Methods. Only the 4 day release is represented above. Harvested samples were plated on a 96 well plate and ELISA performed to quantitate the biotinylated A -42 peptide. Experiments were repeated and were calculated as Mean ± SE (N = 3) and expressed as pmols A -42/mL of binding solution. Graded concentrations of biotinylated A -42 peptide was used as a calibration standard.
Assessment of Release
At the end of each experiment, determination of (gelbound) A release or leakage back to the medium was studied. Gels were washed several times and placed in PB for many days. Samples of the media were harvested after 4 days and A -42 was measured. The results showed negligible or no release of A -42 peptide back into the medium even after 4 days.
Binding of Biotinylated A -42 Peptides to Detox Gels in a Ten-Fold Diluted Environment
In the preceding experiment, detox gels were incubated in 1 mL of binding solution containing 1.5 g A -42. The high concentration of A -42 in the surrounding medium might have contributed favorably towards its binding on the gels. In order to address this possible artifact, we performed binding experiments with increased volume (10mL) containing the same total amount of A -42 (1.5 g) but at one-tenth the concentration (0.15 g/mL). Results showed that there was no significant changes in the binding properties of the detox gels even at 10 fold dilutions A -42 availability. These results suggest that the concentration of A -42 did not influence the observed binding in the previous experiment (Fig.  3) . Fig. (3) . Binding of biotinylated A -42 peptide to detox gel. Binding experiment performed with the detox gel (RI gel) and control gels as denoted. Binding assay was performed as described in the methods section. Pre-swelled individual gels were incubated in the binding solution containing phosphate buffer (10 mM, pH 7), biotinylated A -42 peptide (0.15 g/mL) at 37 0 C. Samples were harvested at 0, 30, 60,90 and 120 minutes. Then the gels were washed and incubated in buffer containing no biotinylated A -42 peptide for up to 4 days at 37 0 C. Samples were collected at the end of 1 and 4 days to assess the release of the biotinylated A -42 peptide back into the medium. Harvested samples were plated on a 96 well plate and ELISA performed to quantitate the biotinylated A -42 peptide. Experiments were repeated and were calculated as Mean ± SE (N = 3) and expressed as pmols A -42/mL of binding solution. Graded concentrations of biotinylated A -42 peptide was used as a calibration standard.
Determination of Binding Capacity
To accomplish this, we performed a binding experiment wherein we pre-incubated detox (RI monomer) gel with excess amount of unbiotinylated A -42 peptide (a nearly 3-fold excess of a different form of A -42 peptide). This preincubation was performed in order to block all the binding elements so that subsequent binding of biotinylated A -42 peptide would not be possible. This would provide another line of evidence for the specificity of the binding of A -42 peptide to the detox gels. As anticipated, the blocked detox gel was unable to bind any biotinylated A -42 peptide whereas the unblocked gel showed gradual binding of A -42 from the surrounding medium (Fig. 4) . Fig. (4) . Pre-blocking with a different A -42 peptide prevents binding of biotinylated A -42 peptide to detox gels. Pre-incubation of RI gel with 4 ug/mL of unbiotinylated A -42 peptide was allowed for 12 h at 37 o C prior to performing a standard binding experiment. A -42 peptide levels in the medium were measured at different time points and compared between the blocked and unblocked detox gels. Binding experiment was performed as described in the methods section. Pre-swelled individual gels were incubated in the binding solution containing phosphate buffer (10 mM, pH 7), biotinylated A -42 peptide (1.5 g/mL) at 37 0 C. Samples were harvested at 0, 30, 60 and 120 minutes. Harvested samples were plated on a 96 well plate and ELISA performed to quantitate the biotinylated A -42 peptide. Experiments were repeated and were calculated as Mean ± SE (N = 3) and expressed as pmols A -42/mL of binding solution. Graded concentrations of biotinylated A -42 peptide was used as a calibration standard.
Amino Acid Analysis
We performed amino acid analysis (AAA) as a way of evaluating the RI: A -42 binding directly. AAA would confirm the presence of A -42 peptide in detox gels after the binding experiment. Therefore, representative gels (placebo and RI gels, pre-and post-binding) were washed in HPLC grade water and were analyzed at WB Keck Foundation for Biotechnology at Yale University. The background from placebo gel was used to normalize the results from RI gels pre-and post-binding experiment. At the Keck laboratory the gels were digested in 6 N HCl. Any peptide present in the gel would be hydrolyzed into its constituent amino acid subunits, which are then analyzed, by ion-exchange chromatography and post-column reaction with ninhydrin. In our application, this method is being pushed to its limit of detection and its accuracy due to false peaks generated from the gel background. Still, after subtracting data from a blank gel we can deduce the following: A gel containing RI peptide prior to binding A -42 gave the results: valine (10 nmols), leucine (9.6 nmols) and phenylalanine (19 nmols) . These values (1.0:0.96:1.9) agree with the expected molar ratios (1:1:2) in the RI peptide, phe-phe-val-leu-lys. Lysine could not be measured due to high background, but the hydrophobic amino acids elute in a clear region of the chromatogram.
We can also deduce that the absolute amount of RI peptide in the gel is 9.8 nmols (average of the 3 amino acids). A gel containing RI peptide post binding A -42 gave similar results, except there was, in addition, about one-tenth the amount of the hydrophobic amino acids, isoleucine and tyrosine, which are in the A -42 peptide but not in RI peptide. We deduce that the gel had captured between 2% (based on isoleucine) and 15% (based on tyrosine) of A -42 peptide, which is between 200 and 1,400 pmols. The value according to ELISA was typically around 250 pmols.
DISCUSSION
Based on numerous studies, it is now accepted that plaques in the brain are responsible for the neurodegenerative process in Alzheimer's disease (AD). These plaques arise from aggregation of the amyloidogenic peptide, A -42 and its truncated form, A -40. These peptides are derived by proteolytic processing of the amyloid precursor protein, which has no known function. In normal brain, these A peptides are eliminated by natural mechanisms. However, with advanced age (>70) and/or with certain mutations that increase proteolytic production of A peptides, or that decrease metabolic breakdown of A peptides, the concentration of A peptides increases in the brain. As a consequence, these otherwise soluble peptides aggregate into an insoluble, neurotoxic, beta-sheet structure. The objective of this proposal is to develop a therapeutic agent to remove and/or prevent further plaque growth.
A few years ago, a novel strategy based on attracting A peptides into the periphery was demonstrated [15] . In their procedure, anti-A monoclonal antibodies were given intravenously. Whereas these antibodies should not normally cross the blood-brain barrier (BBB), the BBB is known to become more permeable in concert with the content of A in the brain [16] . In any case, the antibodies acted as a "peripheral sink", causing blood levels of A peptides to increase substantially (10 to 40 fold) in both normal healthy mice and in mice genetically altered to be a model of human AD. These increased blood levels, when measured as the 24 hour AUC (i.e. the area under the curve of blood concentration as a function of time), did correlate with the amount of plaque in the brain, as measured upon autopsy of the model mice. Despite these promising findings, unfortunately, anti-A antibodies may not be allowed for human use due to toxicity encountered in recent human clinical trials [17] . Continuing on the peripheral sink concept, but using only nonimmunological compounds to bind A , Matsuoka et al. [18, 19] studied various substances, including the well-known stain for AD, Congo Red. A 3-week trial of peripherally administered Congo red (i.e. 3 different analogs) had no effect on brain load of A .
We are also following this research paradigm, but by developing a hydrogel based detoxification depot. The rationale for this approach is that the detoxification depot will be able to sequester toxic A peptides to such an extent that the amount of free (i.e. non-sequestered) A peptides remaining in the brain will be insufficient for plaque formation. To attain this goal, we have designed a device composed of a relatively inert gel bearing multiple copies of the peptide-like sequestering agent. The unique composition and the extraordinary properties of this detoxification gel may prove to be capable of fulfilling its therapeutic function (Fig.  5) . First, the effect of binding of A peptides to each of several RI peptides was evaluated. Different RI peptide encoding detox depots showed variable affinity to A peptides. PEG was used as a platform to congregate the RI peptides because of its inertness and safety. PEG is widely used as a component of various pharmaceutical products that can be delivered parenterally, topically and orally [11] . We designed, synthesized and tested a monomer, dimer and tetramer version of RI peptide. The sequences of these peptides are given in the methods section. Initially we immobilized these peptides on a solid support and tested their binding to A -42. The tetramer peptide bound more A -42 than the monomer and dimer (Fig. 1) . These results confirmed the authenticity of binding of RI peptide to A -42 and demonstrated the compounded binding of multiple copies of ffvlk motif to A -42. Similar results were obtained when the binding study was performed with detox gels incorporating these peptides (Fig. 2) . In a subsequent experiment, a ten-fold dilution of A -42 did not affect its binding to these gels showing the high affinity of this binding (Fig. 3) . Further, since circulating levels of A -42 in patients with Alzheimer's disease is about 50-76 pM [12] , this experiment was an attempt to use lower levels towards physiological level of A -42. The specificity of A -42 capture was also determined by a preblocking experiment detailed in the methods section. In this experiment, detox (RI) gel was incubated with excess amount of unbiotinylated A -42 peptide prior to the binding experiment. This blocking experiment whereby pre-saturated detox gels showed little or no binding of A -42 provided yet another line of proof for the specificity of this binding. Further, this binding was irreversible since there was no release of the gel-bound peptides even several days after the binding experiment. Since there was no efflux of the captured amyloid peptide, detox gels can potentially be used as gel depot/ sink to collect A -42. This observation is critical to address the detox depot's safety for eventual application in murine or human studies. Amino acid analysis of the detox gel bound to A -42 revealed that its amino acid composition matched the RI or and A -42 sequences.
Studies have shown that hydrophobic residues 17-20 of A -42 are vital for its configuration to beta sheets and for its amyloidogenic properties. The peptide KLVFF (corresponding to A 16-20) consisting of structurally different D amino acids and its retro-inverso analogue, ffvlk display consistently high A binding capacity preventing its accruing into amyloid fibrils and therefore are preferable candidates for use as target recognition elements [13] . The retro-inverso analog has great affinity for fibrils and is composed of peptidase-resistant D-amino acids. Our studies were based on retro-inverso peptides (ffvlk) with different copy numbers that have strong and specific binding properties for the neurotoxic A -42 and substantiated previous studies on the binding of A -42 [8] . The retro-inverso motif is otherwise an ordinary peptide except that it is made from the D-isomer (i.e. inverso) of each amino acid rather than from the Lisomer. Inverso peptides are rarely seen in higher organisms. Since inverso peptides are generally resistant to degradation by peptidases, they are much more stable in vivo than their physiological L-amino acid counterparts and therefore have acceptable bioavailability. The retro configuration involves reversing the sequence of the amino acids, whereby the Nterminal residue is at the C-terminus and vice versa. This "retro" change is done to compensate for the spatial orientation of the "inverso" side chains. As a result, the side chains are identical in 3-dimensional space. What is different is that the backbone of the peptide chain in an RI peptide chain has the opposite polarity of the natural peptide. Several treatment modalities for AD have been proposed. One such concept is inhibiting the accumulation of plaques in the brain by interfering with its circulating levels [14] . Thus it might be possible to tip the balance toward removal rather than accumulation of A in the CNS, based on the premise that A equilibrates between the CNS and the periphery. Our hypothesis is based on this concept. Our hypothetical therapeutic strategy is that the remedial reagent does not have to cross the BBB. Instead, the toxic A peptides will cross the BBB and shall be captured in the periphery. Our current results support this strategy. The major outcome of the present study is the determination of the binding efficacy of a detox depot to capture A -42 peptides. Another outcome is the finding that increasing the copy number of ffvlk retro inverso peptide onto the PEG gel has resulted in increased capability of binding A -42 in vitro. Based on these results, the detox gels could potentially be used to prevent the assembly of amyloid fibrils in vivo. Since it is not necessary for the therapeutic agent to cross the BBB, the gel will produce a detox sink effect by shifting the equilibrium of A levels between the central nervous system and plasma. The binding specificity, avidity and the biological safety of the detox gels suggest that these gels could be tested in experimental models of Alzheimer's disease.
